Merit Medical Systems Inc. held its Q2 2025 Earnings Conference Call on July 30, 2025. The event was attended by key corporate figures including Fred Lampropoulos, Chairman and CEO, Raul Parra, Chief Financial Officer, and Brian Lloyd, Chief Legal Officer. Analysts from various financial institutions participated, contributing to a comprehensive discussion on the company's recent developments. During the call, Fred Lampropoulos highlighted two significant announcements. On May 20, 2025, Merit Medical acquired Biolife Delaware, L.L.C. for $120 million. This acquisition aims to broaden Merit's product offerings in post-procedure care with Biolife's patented hemostatic devices, StatSeal and WoundSeal. "This strategic acquisition positions Merit to provide clinicians with more products designed to standardize, simplify and minimize post-procedure care and maintenance," stated Lampropoulos. Another key announcement was the appointment of Martha Aronson as the new President and CEO, effective October 3, 2025. Lampropoulos expressed his enthusiasm, saying, "I'm very excited to welcome Martha to Merit and believe that she is uniquely qualified to lead the company into the future." The full transcript can be accessed through the link below.